Lyell, Pact combine T cell techs to take on solid tumors

Two T cell companies strike a deal to develop personalized, exhaustion-resistant solid tumor therapies

Lyell and Pact think the union of their T cell engineering technologies could overcome the roadblocks hampering cell therapies for solid tumors. While the partners are still pursuing independent pipelines, the joint program could ultimately become both companies’ next-generation platform.

The deal is Lyell Immunopharma Inc.’s first since its under the radar $493 million series C round in March, the year’s largest venture raise so far.


Read the full 653 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers